← Leaderboards
L Darryl Quarles
Duke University
$19,109,320
Attributed
$19,853,101
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$19,853,101 · 15
By mechanism
R01$17,557,195 · 9
R61$752,128 · 1
T32$544,120 · 2
R33$380,000 · 1
R56$370,000 · 1
R41$249,658 · 1
Top collaborators
- Lu Lu3 shared
Most similar at Duke University
Same institution · by research overlap
- David C. Steffens$35,311,674
- Dennis Alan Turner$11,694,617
- Michael Peter Vitek$14,740,646
- Christine M Hulette$2,587,619
- Alexandra Badea$5,771,767
Others in their field
Top investigators on “Osteoblasts”
- Gerard Karsenty · University Of Texas Md Anderson Can Ctr$29,617,439
- Clifford J Rosen · Icahn School Of Medicine At Mount Sinai$20,700,088
- Henry M Kronenberg · Massachusetts General Hospital$20,551,682
- Brendan Hl Lee · Baylor College Of Medicine$20,273,696
- Stavroula Kousteni · Columbia University Health Sciences$19,552,379
- Ernesto Canalis · University Of Connecticut Sch Of Med/Dnt$18,574,878
Research focus
OsteoblastsMediatingHomeostasisOsteogenesisComplexIn VivoIn VitroBoneLinkCellsReceptorLeadMolecularGeneticOsteocalcinPathway InteractionsResponseBaseSignal TransductionPhenotypeRegulationKidneyPlayMetabolism
Grant awards (64)
Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.$249,658
R41 · FY2023 · AG · contact PI
Genetic and Environmental Determinants of GPRC6A Regulation of Energy Metabolism Using Genetically Engineered Mice and Systems Biology$495,854
R01 · FY2022 · DK · contact PI
Genetic and Environmental Determinants of GPRC6A Regulation of Energy Metabolism Using Genetically Engineered Mice and Systems Biology$495,854
R01 · FY2021 · DK · contact PI
Skeletal Functions of Polycystins and TAZ$324,368
R01 · FY2021 · AR · contact PI
Optimization of Novel Small Molecules to Antagonize FGF-23$304,000
R01 · FY2021 · DK · contact PI
Genetic and Environmental Determinants of GPRC6A Regulation of Energy Metabolism Using Genetically Engineered Mice and Systems Biology$495,854
R01 · FY2020 · DK · contact PI
Polycystins/TAZ as a novel therapeutic target to treat osteoporosis$380,000
R33 · FY2020 · AR · contact PI
Skeletal Functions of Polycystins and TAZ$334,400
R01 · FY2020 · AR · contact PI
Optimization of Novel Small Molecules to Antagonize FGF-23$304,000
R01 · FY2020 · DK · contact PI
Polycystins/TAZ as a novel therapeutic target to treat osteoporosis$372,634
R61 · FY2019 · AR · contact PI
Skeletal Functions of Polycystins and TAZ$334,400
R01 · FY2019 · AR · contact PI
Optimization of Novel Small Molecules to Antagonize FGF-23$304,000
R01 · FY2019 · DK · contact PI
Polycystins/TAZ as a novel therapeutic target to treat osteoporosis$379,494
R61 · FY2018 · AR · contact PI
Skeletal Functions of Polycystins and TAZ$300,960
R01 · FY2018 · AR · contact PI
Regulation and Function of FGF23$364,967
R01 · FY2016 · AR · contact PI
Discovery of an Osteocalcin Sensing GPCR Regulating Beta-Cell Function$345,000
R01 · FY2016 · DK · contact PI
Regulation and Function of FGF23$364,967
R01 · FY2015 · AR · contact PI
Discovery of an Osteocalcin Sensing GPCR Regulating Beta-Cell Function$345,000
R01 · FY2015 · DK · contact PI
Regulation and Function of FGF23$357,668
R01 · FY2014 · AR · contact PI
Discovery of an Osteocalcin Sensing GPCR Regulating Beta-Cell Function$345,000
R01 · FY2014 · DK · contact PI
Extrarenal Functions of Polycystin-1$304,029
R01 · FY2014 · DK · contact PI
Regulation and Function of FGF23$150,000
R01 · FY2014 · AR · contact PI
Regulation and Function of FGF23$346,718
R01 · FY2013 · AR · contact PI
Discovery of an Osteocalcin Sensing GPCR Regulating Beta-Cell Function$345,000
R01 · FY2013 · DK · contact PI
Extrarenal Functions of Polycystin-1$293,388
R01 · FY2013 · DK · contact PI
Regulation and Function of FGF23$364,965
R01 · FY2012 · AR · contact PI
Extrarenal Functions of Polycystin-1$304,029
R01 · FY2012 · DK · contact PI
Extrarenal Functions of Polycystin-1$304,029
R01 · FY2011 · DK · contact PI
Extrarenal Functions of Polycystin-1$370,000
R01 · FY2010 · DK · contact PI
Regulation and Function of FGF23$370,000
R56 · FY2009 · AR · contact PI
EXTRACELLULAR CALCIUM-SENSING RECEPTORS IN OSTEOBLASTS$272,804
R01 · FY2009 · AR · contact PI
EXTRACELLULAR CALCIUM-SENSING RECEPTORS IN OSTEOBLASTS$6,006
R01 · FY2009 · AR · contact PI
Pathogenesis of XLH/Hyp: Role of Phex MEPE and FGF23$300,509
R01 · FY2008 · AR · contact PI
EXTRACELLULAR CALCIUM-SENSING RECEPTORS IN OSTEOBLASTS$276,967
R01 · FY2008 · AR · contact PI
University of Kansas Training Grant in Nephrology$126,487
T32 · FY2008 · DK · contact PI
DIFFERENTIAL FUNCTION AND REGULATION OF RUNX2 ISOFORMS$311,869
R01 · FY2007 · AR · contact PI
Pathogenesis of XLH/Hyp: Role of Phex MEPE and FGF23$306,642
R01 · FY2007 · AR · contact PI
EXTRACELLULAR CALCIUM-SENSING RECEPTORS IN OSTEOBLASTS$282,619
R01 · FY2007 · AR · contact PI
University of Kansas Training Grant in Nephrology$120,020
T32 · FY2007 · DK · contact PI
DIFFERENTIAL FUNCTION AND REGULATION OF RUNX2 ISOFORMS$321,183
R01 · FY2006 · AR · contact PI
Pathogenesis of XLH/Hyp: Role of Phex MEPE and FGF23$315,800
R01 · FY2006 · AR · contact PI
EXTRACELLULAR CALCIUM-SENSING RECEPTORS IN OSTEOBLASTS$291,060
R01 · FY2006 · AR · contact PI
University of Kansas Training Grant in Nephrology$123,079
T32 · FY2006 · DK · contact PI
DIFFERENTIAL FUNCTION AND REGULATION OF RUNX2 ISOFORMS$356,475
R01 · FY2005 · AR
PHARMACOLOGICALLY INDUCED NEO-OSTEOGENESIS$349,125
R01 · FY2005 · AR
Pathogenesis of XLH/Hyp: Role of Phex MEPE and FGF23$323,400
R01 · FY2005 · AR
DIFFERENTIAL FUNCTION AND REGULATION OF RUNX2 ISOFORMS$356,475
R01 · FY2004 · AR
Pathogenesis of XLH/Hyp: Role of Phex MEPE and FGF23$323,400
R01 · FY2004 · AR
PHARMACOLOGICALLY INDUCED NEO-OSTEOGENESIS$285,915
R01 · FY2004 · AR
PHARMACOLOGICALLY INDUCED NEO-OSTEOGENESIS$66,220
R01 · FY2004 · AR
PHARMACOLOGICALLY INDUCED NEO-OSTEOGENESIS$365,750
R01 · FY2003 · AR
PEX FUNCTION IN OSTEOBLASTS$333,800
R01 · FY2003 · AR
DIFFERENTIAL FUNCTION AND REGULATION OF RUNX2 ISOFORMS$257,728
R01 · FY2003 · AR
DIFFERENTIAL FUNCTION AND REGULATION OF RUNX2 ISOFORMS$103,450
R01 · FY2003 · AR
GENETICS OF FAMILIAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS$389,141
R01 · FY2002 · DK
PHARMACOLOGICALLY INDUCED NEO-OSTEOGENESIS$365,750
R01 · FY2002 · AR
PEX FUNCTION IN OSTEOBLASTS$327,161
R01 · FY2002 · AR
GENETICS OF FAMILIAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS$377,807
R01 · FY2001 · DK
PHARMACOLOGICALLY INDUCED NEO-OSTEOGENESIS$365,750
R01 · FY2001 · AR
PEX FUNCTION IN OSTEOBLASTS$320,720
R01 · FY2001 · AR
GENETICS OF FAMILIAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS$366,804
R01 · FY2000 · DK
PHARMACOLOGICALLY INDUCED NEO-OSTEOGENESIS$326,442
R01 · FY2000 · AR
PEX FUNCTION IN OSTEOBLASTS$311,973
R01 · FY2000 · AR
ENDOCRINOLOGY AND DIABETES TRAINING PROGRAM$174,534
T32 · FY2000 · DK